| Tubulin inhibitor-based antibody-drug conjugates for cancer therapy H Chen, Z Lin, KE Arnst, DD Miller, W Li Molecules 22 (8), 1281, 2017 | 207 | 2017 |
| Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy KE Arnst, S Banerjee, H Chen, S Deng, DJ Hwang, W Li, DD Miller Medicinal research reviews 39 (4), 1398-1426, 2019 | 139 | 2019 |
| Mechanism of microtubule stabilization by taccalonolide AJ Y Wang, Y Yu, GB Li, SA Li, C Wu, B Gigant, W Qin, H Chen, Y Wu, ... Nature communications 8 (1), 15787, 2017 | 78 | 2017 |
| Polycystin-1 interacts with TAZ to stimulate osteoblastogenesis and inhibit adipogenesis Z Xiao, J Baudry, L Cao, J Huang, H Chen, CR Yates, W Li, B Dong, ... The Journal of clinical investigation 128 (1), 157-174, 2018 | 76 | 2018 |
| DYRK1A inhibitors for disease therapy: Current status and perspectives T Liu, Y Wang, J Wang, C Ren, H Chen, J Zhang European journal of medicinal chemistry 229, 114062, 2022 | 75 | 2022 |
| Design, synthesis, and anticancer evaluation of novel quinoline derivatives of ursolic acid with hydrazide, oxadiazole, and thiadiazole moieties as potent MEK inhibitors XY Jin, H Chen, DD Li, AL Li, WY Wang, W Gu Journal of enzyme inhibition and medicinal chemistry 34 (1), 955-972, 2019 | 67 | 2019 |
| Design, synthesis and in vitro anticancer activity of novel quinoline and oxadiazole derivatives of ursolic acid W Gu, XY Jin, DD Li, SF Wang, XB Tao, H Chen Bioorganic & Medicinal Chemistry Letters 27 (17), 4128-4132, 2017 | 65 | 2017 |
| Structural modification of the 3, 4, 5-trimethoxyphenyl moiety in the tubulin inhibitor VERU-111 leads to improved antiproliferative activities Q Wang, KE Arnst, Y Wang, G Kumar, D Ma, H Chen, Z Wu, J Yang, ... Journal of medicinal chemistry 61 (17), 7877-7891, 2018 | 49 | 2018 |
| A novel carbazole-based mitochondria-targeted ratiometric fluorescent probe for bisulfite in living cells G Wang, H Chen, X Chen, Y Xie Rsc Advances 6 (22), 18662-18666, 2016 | 49 | 2016 |
| Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates Y Yao, L Yu, X Su, Y Wang, W Li, Y Wu, X Cheng, H Zhang, X Wei, ... Journal of Controlled Release 220, 5-17, 2015 | 48 | 2015 |
| Design, synthesis, and biological evaluation of stable colchicine-binding site tubulin inhibitors 6-aryl-2-benzoyl-pyridines as potential anticancer agents H Chen, S Deng, N Albadari, MK Yun, S Zhang, Y Li, D Ma, DN Parke, ... Journal of medicinal chemistry 64 (16), 12049-12074, 2021 | 40 | 2021 |
| Structure–activity relationship study of novel 6-Aryl-2-benzoyl-pyridines as tubulin polymerization inhibitors with potent antiproliferative properties H Chen, S Deng, Y Wang, N Albadari, G Kumar, D Ma, W Li, SW White, ... Journal of Medicinal Chemistry 63 (2), 827-846, 2019 | 39 | 2019 |
| A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells M Hu, C Yang, Y Luo, F Chen, F Yang, S Yang, H Chen, Z Cheng, K Li, ... Journal of materials chemistry B 6 (16), 2413-2416, 2018 | 35 | 2018 |
| Synthesis and biological evaluation of 2-aryl-benzimidazole derivatives of dehydroabietic acid as novel tubulin polymerization inhibitors TT Miao, XB Tao, DD Li, H Chen, XY Jin, Y Geng, SF Wang, W Gu RSC advances 8 (31), 17511-17526, 2018 | 35 | 2018 |
| An orally available tubulin inhibitor, VERU-111, suppresses triple-negative breast cancer tumor growth and metastasis and bypasses taxane resistance S Deng, RI Krutilina, Q Wang, Z Lin, DN Parke, HC Playa, H Chen, ... Molecular cancer therapeutics 19 (2), 348-363, 2020 | 34 | 2020 |
| Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site Q Lai, Y Wang, R Wang, W Lai, L Tang, Y Tao, Y Liu, R Zhang, L Huang, ... European Journal of Medicinal Chemistry 156, 162-179, 2018 | 34 | 2018 |
| 1α,20S-Dihydroxyvitamin D3 Interacts with Vitamin D Receptor: Crystal Structure and Route of Chemical Synthesis Z Lin, H Chen, AY Belorusova, JC Bollinger, EKY Tang, Z Janjetovic, ... Scientific reports 7 (1), 10193, 2017 | 34 | 2017 |
| Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer F Mahmud, S Deng, H Chen, DD Miller, W Li Cancer letters 495, 76-88, 2020 | 29 | 2020 |
| Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities X Hu, J Zhang, Y Zhang, F Jiao, J Wang, H Chen, L Ouyang, Y Wang European Journal of Medicinal Chemistry 230, 114094, 2022 | 28 | 2022 |
| Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies Q Lai, M Wu, R Wang, W Lai, Y Tao, Y Lu, Y Wang, L Yu, R Zhang, ... European Journal of Medicinal Chemistry 199, 112364, 2020 | 25 | 2020 |